Related Experiment Videos
Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking
1University of Colorado Health Sciences Center, Division of Cardiology, Denver 80262.
Insights
Beta-blocking agents can improve cardiac function and slow disease progression in heart failure patients by counteracting harmful neurohormonal effects. Further large-scale trials are needed to confirm their long-term impact on heart failure outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure involves complex neurohormonal compensatory mechanisms.
- Therapeutic strategies targeting these mechanisms can improve patient outcomes.
Purpose of the Study:
- To evaluate the role of beta-adrenergic receptor antagonists in managing heart failure.
- To explore the mechanisms by which beta-blockers affect cardiac function and disease progression.
Main Methods:
- Review of clinical data and controlled long-term studies on beta-blocker therapy in heart failure.
- Analysis of the effects of beta-adrenergic receptor antagonists on myocardial function and hemodynamics.
Main Results:
- Beta-blocking agents demonstrate efficacy in improving cardiac function and hemodynamics in chronic heart failure.
- These agents exert beneficial effects through neurohormonal antagonism, similar to ACE inhibitors.
Conclusions:
- Beta-blocker therapy offers a promising approach to managing heart failure by targeting neurohormonal imbalances.
- Additional large-scale trials are necessary to definitively establish the long-term benefits of beta-blockers on the natural history of heart failure.
Abstract:
An understanding of the important role of neurohormonal compensatory mechanisms in heart failure has been translated into therapeutic options that can improve cardiac function, alter disease progression, and improve survival. Angiotensin-converting enzyme inhibitors are of proven benefit in this regard, and beta-adrenergic receptor antagonists are potentially another such class of agents. By inhibiting the myocardial effects of chronic adrenergic activation, beta blocking agents may improve left ventricular function or delay its deterioration in patients with heart failure. Aside from blocking beta-adrenergic receptors, other ancillary properties inherent in third-generation beta-blocking agents (such as vasodilation) may exert additional favorable effects. Clinical data generated in subjects with heart failure indicate that beta-antagonist therapy exerts its physiologic and clinical effects through neurohormonal antagonism, generally analogous to angiotensin-converting enzyme inhibitors. Virtually all controlled long-term studies show that beta-blocking agents improve cardiac function and hemodynamics in patients with chronic heart failure, but large-scale trials are needed to ascertain a favorable effect on the natural history of heart failure.